new BindingDB logo
myBDB logout
Compile Data Set for Download or QSAR

Found 469 hits of ic50 for UniProtKB: P21462   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kcal/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050929
PNG
(2-((S)-2-{(S)-2-[3-(4-Methoxy-phenyl)-ureido]-4-me...)
Show SMILES COc1ccc(NC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)NC(Cc2ccccc2)C(O)=O)cc1
Show InChI InChI=1S/C28H38N4O6S/c1-18(2)16-23(26(34)31-24(27(35)36)17-19-8-6-5-7-9-19)30-25(33)22(14-15-39-4)32-28(37)29-20-10-12-21(38-3)13-11-20/h5-13,18,22-24H,14-17H2,1-4H3,(H,30,33)(H,31,34)(H,35,36)(H2,29,32,37)/t22-,23-,24?/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 2n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Binding affinity towards fMLF receptor using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050933
PNG
((S)-2-((S)-2-{(S)-2-[3-(4-Chloro-phenyl)-ureido]-4...)
Show SMILES CSCC[C@H](NC(=O)Nc1ccc(Cl)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O
Show InChI InChI=1S/C27H35ClN4O5S/c1-17(2)15-22(25(34)31-23(26(35)36)16-18-7-5-4-6-8-18)30-24(33)21(13-14-38-3)32-27(37)29-20-11-9-19(28)10-12-20/h4-12,17,21-23H,13-16H2,1-3H3,(H,30,33)(H,31,34)(H,35,36)(H2,29,32,37)/t21-,22-,23-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 2n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Binding affinity towards fMLF receptor using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050935
PNG
((S)-2-{(S)-4-Methyl-2-[(S)-4-methylsulfanyl-2-(3-p...)
Show SMILES CSCC[C@H](NC(=O)Nc1ccc(C)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O
Show InChI InChI=1S/C28H38N4O5S/c1-18(2)16-23(26(34)31-24(27(35)36)17-20-8-6-5-7-9-20)30-25(33)22(14-15-38-4)32-28(37)29-21-12-10-19(3)11-13-21/h5-13,18,22-24H,14-17H2,1-4H3,(H,30,33)(H,31,34)(H,35,36)(H2,29,32,37)/t22-,23-,24-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 2n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Binding affinity towards fMLF receptor using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419562
PNG
(CHEMBL1934424)
Show SMILES CO[C@H]1CC[C@H](CC1)n1nc(C)c(C(=O)N[C@@H](C)C(C)(C)C)c1NS(=O)(=O)c1ccc(C)cc1 |r,wU:5.8,16.17,2.1,(31.27,-8.16,;32.01,-6.81,;31.21,-5.49,;29.67,-5.52,;28.87,-4.21,;29.61,-2.86,;31.15,-2.82,;31.95,-4.13,;29.13,-1.41,;27.66,-.94,;27.66,.6,;26.41,1.51,;29.12,1.08,;29.59,2.55,;31.1,2.88,;28.56,3.69,;29.03,5.16,;27.99,6.3,;30.53,5.48,;31.57,4.34,;31,6.95,;32.01,5.9,;30.03,-.15,;31.57,-.15,;32.33,1.2,;30.99,1.97,;32.33,2.74,;33.88,1.2,;34.64,-.13,;36.18,-.13,;36.95,1.2,;38.49,1.2,;36.18,2.53,;34.64,2.52,)|
Show InChI InChI=1S/C25H38N4O4S/c1-16-8-14-21(15-9-16)34(31,32)28-23-22(24(30)26-18(3)25(4,5)6)17(2)27-29(23)19-10-12-20(33-7)13-11-19/h8-9,14-15,18-20,28H,10-13H2,1-7H3,(H,26,30)/t18-,19-,20+/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 4n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human recombinant FPR1 in expressed in HEK293 cells assessed as inhibition of FMLP-stimulated intracellular calcium mobilisati...


Bioorg Med Chem Lett 22: 532-6 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.090
BindingDB Entry DOI: 10.7270/Q27P90NM
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419384
PNG
(CHEMBL1916289)
Show SMILES C[C@H](NC(=O)c1c(C)nn(c1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)-c1ccc(F)cc1)C(C)(C)C |r|
Show InChI InChI=1S/C24H26F4N4O3S/c1-14-20(22(33)29-15(2)23(3,4)5)21(32(30-14)18-10-8-17(25)9-11-18)31-36(34,35)19-12-6-16(7-13-19)24(26,27)28/h6-13,15,31H,1-5H3,(H,29,33)/t15-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 13n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assay


Bioorg Med Chem Lett 21: 6456-60 (2011)


Article DOI: 10.1016/j.bmcl.2011.08.085
BindingDB Entry DOI: 10.7270/Q2WD41VZ
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050928
PNG
((S)-2-[(R)-4-Methyl-2-((S)-2-{(R)-4-methyl-2-[(S)-...)
Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)Nc1cccc(C)c1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O
Show InChI InChI=1S/C47H58N6O7/c1-30(2)24-37(50-45(57)40(28-34-19-11-7-12-20-34)53-47(60)48-36-23-15-16-32(5)26-36)42(54)51-39(27-33-17-9-6-10-18-33)44(56)49-38(25-31(3)4)43(55)52-41(46(58)59)29-35-21-13-8-14-22-35/h6-23,26,30-31,37-41H,24-25,27-29H2,1-5H3,(H,49,56)(H,50,57)(H,51,54)(H,52,55)(H,58,59)(H2,48,53,60)/t37-,38-,39+,40+,41+/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 20n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050937
PNG
((S)-2-[(S)-2-((S)-2-Formylamino-4-methylsulfanyl-b...)
Show SMILES CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O
Show InChI InChI=1S/C21H31N3O5S/c1-14(2)11-17(23-19(26)16(22-13-25)9-10-30-3)20(27)24-18(21(28)29)12-15-7-5-4-6-8-15/h4-8,13-14,16-18H,9-12H2,1-3H3,(H,22,25)(H,23,26)(H,24,27)(H,28,29)/t16-,17-,18-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
Purchase

CHEMBL
KEGG
MMDB
PC cid
PC sid
UniChem

Patents

Article
PubMed
n/an/a 20n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Binding affinity towards fMLF receptor using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050945
PNG
((S)-2-[(R)-2-((S)-2-{(R)-2-[(S)-2-(3-Adamantan-1-y...)
Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)NC12CC3CC(CC(C3)C1)C2)C(=O)N[C@@H](Cc1ccccc1)C(O)=O |TLB:42:43:47:41.40.46,46:41:48:45.47.44,46:45:48:41.40.42,THB:42:41:47:43.48.44|
Show InChI InChI=1S/C50H66N6O7/c1-31(2)20-39(52-47(60)42(26-34-16-10-6-11-17-34)55-49(63)56-50-28-36-22-37(29-50)24-38(23-36)30-50)44(57)53-41(25-33-14-8-5-9-15-33)46(59)51-40(21-32(3)4)45(58)54-43(48(61)62)27-35-18-12-7-13-19-35/h5-19,31-32,36-43H,20-30H2,1-4H3,(H,51,59)(H,52,60)(H,53,57)(H,54,58)(H,61,62)(H2,55,56,63)/t36?,37?,38?,39-,40-,41+,42+,43+,50?/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 20n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Binding affinity towards fMLF receptor using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419356
PNG
(CHEMBL1916288)
Show SMILES C[C@H](NC(=O)c1c(C)nn(c1NS(=O)(=O)c1ccc(cc1)C#N)-c1ccc(F)cc1)C(C)(C)C |r|
Show InChI InChI=1S/C24H26FN5O3S/c1-15-21(23(31)27-16(2)24(3,4)5)22(30(28-15)19-10-8-18(25)9-11-19)29-34(32,33)20-12-6-17(14-26)7-13-20/h6-13,16,29H,1-5H3,(H,27,31)/t16-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 25n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human recombinant FPR1 in expressed in HEK293 cells assessed as inhibition of FMLP-stimulated intracellular calcium mobilisati...


Bioorg Med Chem Lett 22: 532-6 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.090
BindingDB Entry DOI: 10.7270/Q27P90NM
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419381
PNG
(CHEMBL1916284)
Show SMILES C[C@H](NC(=O)c1c(NS(=O)(=O)c2ccc(C)cc2)n(nc1C(F)(F)F)-c1ccccc1)C(C)(C)C |r|
Show InChI InChI=1S/C24H27F3N4O3S/c1-15-11-13-18(14-12-15)35(33,34)30-21-19(22(32)28-16(2)23(3,4)5)20(24(25,26)27)29-31(21)17-9-7-6-8-10-17/h6-14,16,30H,1-5H3,(H,28,32)/t16-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 25n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assay


Bioorg Med Chem Lett 21: 6456-60 (2011)


Article DOI: 10.1016/j.bmcl.2011.08.085
BindingDB Entry DOI: 10.7270/Q2WD41VZ
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419356
PNG
(CHEMBL1916288)
Show SMILES C[C@H](NC(=O)c1c(C)nn(c1NS(=O)(=O)c1ccc(cc1)C#N)-c1ccc(F)cc1)C(C)(C)C |r|
Show InChI InChI=1S/C24H26FN5O3S/c1-15-21(23(31)27-16(2)24(3,4)5)22(30(28-15)19-10-8-18(25)9-11-19)29-34(32,33)20-12-6-17(14-26)7-13-20/h6-13,16,29H,1-5H3,(H,27,31)/t16-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 25n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assay


Bioorg Med Chem Lett 21: 6456-60 (2011)


Article DOI: 10.1016/j.bmcl.2011.08.085
BindingDB Entry DOI: 10.7270/Q2WD41VZ
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050946
PNG
((S)-2-{(S)-4-Methyl-2-[(S)-4-methylsulfanyl-2-(3-p...)
Show SMILES CSCC[C@H](NC(=O)Nc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O
Show InChI InChI=1S/C27H36N4O5S/c1-18(2)16-22(25(33)30-23(26(34)35)17-19-10-6-4-7-11-19)29-24(32)21(14-15-37-3)31-27(36)28-20-12-8-5-9-13-20/h4-13,18,21-23H,14-17H2,1-3H3,(H,29,32)(H,30,33)(H,34,35)(H2,28,31,36)/t21-,22-,23-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 30n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Binding affinity towards fMLF receptor using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419568
PNG
(CHEMBL1934415)
Show SMILES C[C@H](NC(=O)c1c(C)nn(C2CCCCC2)c1NS(=O)(=O)c1ccc(C)cc1)C(C)(C)C |r|
Show InChI InChI=1S/C24H36N4O3S/c1-16-12-14-20(15-13-16)32(30,31)27-22-21(23(29)25-18(3)24(4,5)6)17(2)26-28(22)19-10-8-7-9-11-19/h12-15,18-19,27H,7-11H2,1-6H3,(H,25,29)/t18-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 32n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human recombinant FPR1 in expressed in HEK293 cells assessed as inhibition of FMLP-stimulated intracellular calcium mobilisati...


Bioorg Med Chem Lett 22: 532-6 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.090
BindingDB Entry DOI: 10.7270/Q27P90NM
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419565
PNG
(CHEMBL1934418)
Show SMILES C[C@H](NC(=O)c1c(C)nn(C2CCSCC2)c1NS(=O)(=O)c1ccc(C)cc1)C(C)(C)C |r|
Show InChI InChI=1S/C23H34N4O3S2/c1-15-7-9-19(10-8-15)32(29,30)26-21-20(22(28)24-17(3)23(4,5)6)16(2)25-27(21)18-11-13-31-14-12-18/h7-10,17-18,26H,11-14H2,1-6H3,(H,24,28)/t17-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 40n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human recombinant FPR1 in expressed in HEK293 cells assessed as inhibition of FMLP-stimulated intracellular calcium mobilisati...


Bioorg Med Chem Lett 22: 532-6 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.090
BindingDB Entry DOI: 10.7270/Q27P90NM
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050942
PNG
((S)-2-[(R)-4-Methyl-2-((S)-2-{(R)-4-methyl-2-[(S)-...)
Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)Nc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O
Show InChI InChI=1S/C46H56N6O7/c1-30(2)25-36(49-44(56)39(28-33-19-11-6-12-20-33)52-46(59)47-35-23-15-8-16-24-35)41(53)50-38(27-32-17-9-5-10-18-32)43(55)48-37(26-31(3)4)42(54)51-40(45(57)58)29-34-21-13-7-14-22-34/h5-24,30-31,36-40H,25-29H2,1-4H3,(H,48,55)(H,49,56)(H,50,53)(H,51,54)(H,57,58)(H2,47,52,59)/t36-,37-,38+,39+,40+/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 50n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Binding affinity towards fMLF receptor using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419577
PNG
(CHEMBL1934414)
Show SMILES C[C@H](NC(=O)c1c(C)nn(C2CCCC2)c1NS(=O)(=O)c1ccc(C)cc1)C(C)(C)C |r|
Show InChI InChI=1S/C23H34N4O3S/c1-15-11-13-19(14-12-15)31(29,30)26-21-20(22(28)24-17(3)23(4,5)6)16(2)25-27(21)18-9-7-8-10-18/h11-14,17-18,26H,7-10H2,1-6H3,(H,24,28)/t17-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 79n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human recombinant FPR1 in expressed in HEK293 cells assessed as inhibition of FMLP-stimulated intracellular calcium mobilisati...


Bioorg Med Chem Lett 22: 532-6 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.090
BindingDB Entry DOI: 10.7270/Q27P90NM
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419372
PNG
(CHEMBL1916271)
Show SMILES CCN(C1CCCCC1)C(=O)c1cnn(c1NS(=O)(=O)c1ccc(cc1)-c1cnco1)-c1ccccc1
Show InChI InChI=1S/C27H29N5O4S/c1-2-31(21-9-5-3-6-10-21)27(33)24-17-29-32(22-11-7-4-8-12-22)26(24)30-37(34,35)23-15-13-20(14-16-23)25-18-28-19-36-25/h4,7-8,11-19,21,30H,2-3,5-6,9-10H2,1H3
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 79n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assay


Bioorg Med Chem Lett 21: 6456-60 (2011)


Article DOI: 10.1016/j.bmcl.2011.08.085
BindingDB Entry DOI: 10.7270/Q2WD41VZ
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419355
PNG
(CHEMBL1916282)
Show SMILES C[C@H](NC(=O)c1c(C)nn(c1NS(=O)(=O)c1ccc(C)cc1)-c1ccccc1)C(C)(C)C |r|
Show InChI InChI=1S/C24H30N4O3S/c1-16-12-14-20(15-13-16)32(30,31)27-22-21(23(29)25-18(3)24(4,5)6)17(2)26-28(22)19-10-8-7-9-11-19/h7-15,18,27H,1-6H3,(H,25,29)/t18-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 79n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assay


Bioorg Med Chem Lett 21: 6456-60 (2011)


Article DOI: 10.1016/j.bmcl.2011.08.085
BindingDB Entry DOI: 10.7270/Q2WD41VZ
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419355
PNG
(CHEMBL1916282)
Show SMILES C[C@H](NC(=O)c1c(C)nn(c1NS(=O)(=O)c1ccc(C)cc1)-c1ccccc1)C(C)(C)C |r|
Show InChI InChI=1S/C24H30N4O3S/c1-16-12-14-20(15-13-16)32(30,31)27-22-21(23(29)25-18(3)24(4,5)6)17(2)26-28(22)19-10-8-7-9-11-19/h7-15,18,27H,1-6H3,(H,25,29)/t18-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 79n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human recombinant FPR1 in expressed in HEK293 cells assessed as inhibition of FMLP-stimulated intracellular calcium mobilisati...


Bioorg Med Chem Lett 22: 532-6 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.090
BindingDB Entry DOI: 10.7270/Q27P90NM
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050926
PNG
((S)-2-((R)-4-Methyl-2-{(S)-2-[(R)-4-methyl-2-((S)-...)
Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O
Show InChI InChI=1S/C40H52N6O7/c1-25(2)20-30(43-38(50)33(46-40(41)53)23-28-16-10-6-11-17-28)35(47)44-32(22-27-14-8-5-9-15-27)37(49)42-31(21-26(3)4)36(48)45-34(39(51)52)24-29-18-12-7-13-19-29/h5-19,25-26,30-34H,20-24H2,1-4H3,(H,42,49)(H,43,50)(H,44,47)(H,45,48)(H,51,52)(H3,41,46,53)/t30-,31-,32+,33+,34+/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 100n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050939
PNG
((S)-2-{(S)-4-Methyl-2-[(S)-4-methylsulfanyl-2-(3-m...)
Show SMILES CSCC[C@H](NC(=O)Nc1cccc(C)c1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O
Show InChI InChI=1S/C28H38N4O5S/c1-18(2)15-23(26(34)31-24(27(35)36)17-20-10-6-5-7-11-20)30-25(33)22(13-14-38-4)32-28(37)29-21-12-8-9-19(3)16-21/h5-12,16,18,22-24H,13-15,17H2,1-4H3,(H,30,33)(H,31,34)(H,35,36)(H2,29,32,37)/t22-,23-,24-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 100n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Binding affinity towards fMLF receptor using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419355
PNG
(CHEMBL1916282)
Show SMILES C[C@H](NC(=O)c1c(C)nn(c1NS(=O)(=O)c1ccc(C)cc1)-c1ccccc1)C(C)(C)C |r|
Show InChI InChI=1S/C24H30N4O3S/c1-16-12-14-20(15-13-16)32(30,31)27-22-21(23(29)25-18(3)24(4,5)6)17(2)26-28(22)19-10-8-7-9-11-19/h7-15,18,27H,1-6H3,(H,25,29)/t18-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 126n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assay


Bioorg Med Chem Lett 21: 6456-60 (2011)


Article DOI: 10.1016/j.bmcl.2011.08.085
BindingDB Entry DOI: 10.7270/Q2WD41VZ
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50051610
PNG
(CHEMBL3311300)
Show SMILES CC(C)C[C@@H](NC(=O)[C@H](CC1=CCCCC1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(cc1)C(=O)c1ccccc1)NC(=O)OC(C)(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O |r,t:10|
Show InChI InChI=1/C51H67N5O9/c1-32(2)27-39(53-48(61)42(56-50(64)65-51(5,6)7)30-36-23-25-38(26-24-36)44(57)37-21-15-10-16-22-37)45(58)54-41(29-34-17-11-8-12-18-34)47(60)52-40(28-33(3)4)46(59)55-43(49(62)63)31-35-19-13-9-14-20-35/h9-10,13-17,19-26,32-33,39-43H,8,11-12,18,27-31H2,1-7H3,(H,52,60)(H,53,61)(H,54,58)(H,55,59)(H,56,64)(H,62,63)/t39-,40-,41+,42+,43+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
n/an/a 140n/an/an/an/an/an/a



Saga University

Curated by ChEMBL


Assay Description
Antagonist activity at formyl peptide receptor in human HL60 cells assessed as inhibition of fMLP-induced calcium mobilization incubated for 5 mins p...


Bioorg Med Chem 22: 3824-8 (2014)


Article DOI: 10.1016/j.bmc.2014.06.048
BindingDB Entry DOI: 10.7270/Q28S4RK8
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50409610
PNG
(CHEMBL2021596)
Show SMILES CC[C@@H]1NC(=O)[C@H](C(C)C(C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |r|
Show InChI InChI=1S/C63H113N11O11/c1-26-28-29-41(15)42(16)53-57(79)66-45(27-2)59(81)68(19)34-50(75)69(20)46(30-35(3)4)56(78)67-51(39(11)12)62(84)70(21)47(31-36(5)6)55(77)64-43(17)54(76)65-44(18)58(80)71(22)48(32-37(7)8)60(82)72(23)49(33-38(9)10)61(83)73(24)52(40(13)14)63(85)74(53)25/h26,28,35-49,51-53H,27,29-34H2,1-25H3,(H,64,77)(H,65,76)(H,66,79)(H,67,78)/b28-26+/t41?,42?,43-,44+,45-,46-,47-,48-,49-,51-,52+,53-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
PubMed
n/an/a 150n/an/an/an/an/an/a



Strasbourg 1 University

Curated by ChEMBL


Assay Description
Inhibitory activity against human formylpeptide receptor (FPR) of human leukemia HL-60 cells


J Med Chem 45: 4613-28 (2002)


BindingDB Entry DOI: 10.7270/Q2571CQX
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419561
PNG
(CHEMBL1934426)
Show SMILES C[C@H](NC(=O)c1c(C)nn(C2CCOCC2)c1NS(=O)(=O)c1ccc(cc1)C1CC1)C(C)(C)C |r|
Show InChI InChI=1S/C25H36N4O4S/c1-16-22(24(30)26-17(2)25(3,4)5)23(29(27-16)20-12-14-33-15-13-20)28-34(31,32)21-10-8-19(9-11-21)18-6-7-18/h8-11,17-18,20,28H,6-7,12-15H2,1-5H3,(H,26,30)/t17-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 158n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human recombinant FPR1 in expressed in HEK293 cells assessed as inhibition of FMLP-stimulated intracellular calcium mobilisati...


Bioorg Med Chem Lett 22: 532-6 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.090
BindingDB Entry DOI: 10.7270/Q27P90NM
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419376
PNG
(CHEMBL1916277)
Show SMILES CC1CCCCC1NC(=O)c1c(C)nn(c1NS(=O)(=O)c1ccc(C)cc1)-c1ccccc1
Show InChI InChI=1S/C25H30N4O3S/c1-17-13-15-21(16-14-17)33(31,32)28-24-23(25(30)26-22-12-8-7-9-18(22)2)19(3)27-29(24)20-10-5-4-6-11-20/h4-6,10-11,13-16,18,22,28H,7-9,12H2,1-3H3,(H,26,30)
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 158n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assay


Bioorg Med Chem Lett 21: 6456-60 (2011)


Article DOI: 10.1016/j.bmcl.2011.08.085
BindingDB Entry DOI: 10.7270/Q2WD41VZ
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50418335
PNG
(CHEMBL1770297)
Show SMILES CCOc1ccc2oc(C(=O)NC(CCSC)c3nc4ccccc4[nH]3)c(C)c2c1
Show InChI InChI=1S/C23H25N3O3S/c1-4-28-15-9-10-20-16(13-15)14(2)21(29-20)23(27)26-19(11-12-30-3)22-24-17-7-5-6-8-18(17)25-22/h5-10,13,19H,4,11-12H2,1-3H3,(H,24,25)(H,26,27)
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 158n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated degranulation after 15 mins by fluorescence assay


Bioorg Med Chem Lett 21: 2991-7 (2011)


Article DOI: 10.1016/j.bmcl.2011.03.049
BindingDB Entry DOI: 10.7270/Q2PZ5B2D
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419379
PNG
(CHEMBL1916280)
Show SMILES CCC(C)NC(=O)c1c(C)nn(c1NS(=O)(=O)c1ccc(C)cc1)-c1ccccc1
Show InChI InChI=1S/C22H26N4O3S/c1-5-16(3)23-22(27)20-17(4)24-26(18-9-7-6-8-10-18)21(20)25-30(28,29)19-13-11-15(2)12-14-19/h6-14,16,25H,5H2,1-4H3,(H,23,27)
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 158n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assay


Bioorg Med Chem Lett 21: 6456-60 (2011)


Article DOI: 10.1016/j.bmcl.2011.08.085
BindingDB Entry DOI: 10.7270/Q2WD41VZ
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419569
PNG
(CHEMBL1934413)
Show SMILES C[C@H](NC(=O)c1c(C)nn(C2CCC2)c1NS(=O)(=O)c1ccc(C)cc1)C(C)(C)C |r|
Show InChI InChI=1S/C22H32N4O3S/c1-14-10-12-18(13-11-14)30(28,29)25-20-19(21(27)23-16(3)22(4,5)6)15(2)24-26(20)17-8-7-9-17/h10-13,16-17,25H,7-9H2,1-6H3,(H,23,27)/t16-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 200n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human recombinant FPR1 in expressed in HEK293 cells assessed as inhibition of FMLP-stimulated intracellular calcium mobilisati...


Bioorg Med Chem Lett 22: 532-6 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.090
BindingDB Entry DOI: 10.7270/Q27P90NM
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050928
PNG
((S)-2-[(R)-4-Methyl-2-((S)-2-{(R)-4-methyl-2-[(S)-...)
Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)Nc1cccc(C)c1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O
Show InChI InChI=1S/C47H58N6O7/c1-30(2)24-37(50-45(57)40(28-34-19-11-7-12-20-34)53-47(60)48-36-23-15-16-32(5)26-36)42(54)51-39(27-33-17-9-6-10-18-33)44(56)49-38(25-31(3)4)43(55)52-41(46(58)59)29-35-21-13-8-14-22-35/h6-23,26,30-31,37-41H,24-25,27-29H2,1-5H3,(H,49,56)(H,50,57)(H,51,54)(H,52,55)(H,58,59)(H2,48,53,60)/t37-,38-,39+,40+,41+/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 200n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Binding affinity towards fMLF receptor using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050943
PNG
((S)-2-[(R)-2-((S)-2-{(R)-2-[(S)-2-(3-Isopropyl-ure...)
Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)NC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O
Show InChI InChI=1S/C43H58N6O7/c1-27(2)22-33(46-41(53)36(49-43(56)44-29(5)6)25-31-18-12-8-13-19-31)38(50)47-35(24-30-16-10-7-11-17-30)40(52)45-34(23-28(3)4)39(51)48-37(42(54)55)26-32-20-14-9-15-21-32/h7-21,27-29,33-37H,22-26H2,1-6H3,(H,45,52)(H,46,53)(H,47,50)(H,48,51)(H,54,55)(H2,44,49,56)/t33-,34-,35+,36+,37+/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 200n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Binding affinity towards fMLF receptor using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50026897
PNG
(CHEMBL2372488)
Show SMILES [H][C@]1(NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@](O)(NC(=O)[C@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)CNC1=O)C(C)C)[C@@H](C)O |r|
Show InChI InChI=1/C63H113N11O14/c1-24-25-26-40(16)52(77)51-58(83)68-49(42(18)75)57(82)64-32-48(76)70(19)45(29-35(6)7)55(80)66-43(27-33(2)3)59(84)71(20)46(30-36(8)9)54(79)65-41(17)53(78)69-63(88,39(14)15)62(87)72(21)47(31-37(10)11)56(81)67-44(28-34(4)5)60(85)73(22)50(38(12)13)61(86)74(51)23/h24-25,33-47,49-52,75,77,88H,26-32H2,1-23H3,(H,64,82)(H,65,79)(H,66,80)(H,67,81)(H,68,83)(H,69,78)/b25-24+/t40-,41+,42-,43+,44+,45-,46-,47+,49+,50+,51+,52-,63+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
PubMed
n/an/a 300n/an/an/an/an/an/a



Strasbourg 1 University

Curated by ChEMBL


Assay Description
Inhibitory activity against human formylpeptide receptor (FPR) of human leukemia HL-60 cells


J Med Chem 45: 4613-28 (2002)


BindingDB Entry DOI: 10.7270/Q2571CQX
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050927
PNG
((S)-2-{(S)-2-[(S)-2-(3-Isopropenyl-ureido)-4-methy...)
Show SMILES [#6]-[#16]-[#6]-[#6]-[#6@H](-[#7]-[#6](=O)\[#7]=[#6](\[#6])-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6](-[#6])-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccccc1)-[#6](-[#8])=O
Show InChI InChI=1S/C24H36N4O5S/c1-15(2)13-19(22(30)27-20(23(31)32)14-17-9-7-6-8-10-17)26-21(29)18(11-12-34-5)28-24(33)25-16(3)4/h6-10,15,18-20H,11-14H2,1-5H3,(H,26,29)(H,27,30)(H,28,33)(H,31,32)/t18-,19-,20-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 300n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Binding affinity towards fMLF receptor using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050931
PNG
((S)-2-[(R)-2-((S)-2-{(R)-2-[(S)-2-(3-Butyl-ureido)...)
Show SMILES CCCCNC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O
Show InChI InChI=1S/C44H60N6O7/c1-6-7-23-45-44(57)50-37(27-32-19-13-9-14-20-32)42(54)47-34(24-29(2)3)39(51)48-36(26-31-17-11-8-12-18-31)41(53)46-35(25-30(4)5)40(52)49-38(43(55)56)28-33-21-15-10-16-22-33/h8-22,29-30,34-38H,6-7,23-28H2,1-5H3,(H,46,53)(H,47,54)(H,48,51)(H,49,52)(H,55,56)(H2,45,50,57)/t34-,35-,36+,37+,38+/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 300n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Binding affinity towards fMLF receptor using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050945
PNG
((S)-2-[(R)-2-((S)-2-{(R)-2-[(S)-2-(3-Adamantan-1-y...)
Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)NC12CC3CC(CC(C3)C1)C2)C(=O)N[C@@H](Cc1ccccc1)C(O)=O |TLB:42:43:47:41.40.46,46:41:48:45.47.44,46:45:48:41.40.42,THB:42:41:47:43.48.44|
Show InChI InChI=1S/C50H66N6O7/c1-31(2)20-39(52-47(60)42(26-34-16-10-6-11-17-34)55-49(63)56-50-28-36-22-37(29-50)24-38(23-36)30-50)44(57)53-41(25-33-14-8-5-9-15-33)46(59)51-40(21-32(3)4)45(58)54-43(48(61)62)27-35-18-12-7-13-19-35/h5-19,31-32,36-43H,20-30H2,1-4H3,(H,51,59)(H,52,60)(H,53,57)(H,54,58)(H,61,62)(H2,55,56,63)/t36?,37?,38?,39-,40-,41+,42+,43+,50?/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 300n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050934
PNG
((S)-2-{(S)-2-[(S)-2-(3-Butyl-ureido)-4-methylsulfa...)
Show SMILES CCCCNC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O
Show InChI InChI=1S/C25H40N4O5S/c1-5-6-13-26-25(34)29-19(12-14-35-4)22(30)27-20(15-17(2)3)23(31)28-21(24(32)33)16-18-10-8-7-9-11-18/h7-11,17,19-21H,5-6,12-16H2,1-4H3,(H,27,30)(H,28,31)(H,32,33)(H2,26,29,34)/t19-,20-,21-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 300n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Binding affinity towards fMLF receptor using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419575
PNG
(CHEMBL1934422)
Show SMILES C[C@H](NC(=O)c1c(C)nn(C2CCOCC2)c1NS(=O)(=O)c1ccc(C)cc1)C(C)(C)C |r|
Show InChI InChI=1S/C23H34N4O4S/c1-15-7-9-19(10-8-15)32(29,30)26-21-20(22(28)24-17(3)23(4,5)6)16(2)25-27(21)18-11-13-31-14-12-18/h7-10,17-18,26H,11-14H2,1-6H3,(H,24,28)/t17-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 316n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human recombinant FPR1 in expressed in HEK293 cells assessed as inhibition of FMLP-stimulated intracellular calcium mobilisati...


Bioorg Med Chem Lett 22: 532-6 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.090
BindingDB Entry DOI: 10.7270/Q27P90NM
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419387
PNG
(CHEMBL1916255)
Show SMILES CCCC(CC)NC(=O)c1cnn(c1NS(=O)(=O)c1ccc(C)cc1)-c1ccccc1
Show InChI InChI=1S/C23H28N4O3S/c1-4-9-18(5-2)25-23(28)21-16-24-27(19-10-7-6-8-11-19)22(21)26-31(29,30)20-14-12-17(3)13-15-20/h6-8,10-16,18,26H,4-5,9H2,1-3H3,(H,25,28)
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 316n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assay


Bioorg Med Chem Lett 21: 6456-60 (2011)


Article DOI: 10.1016/j.bmcl.2011.08.085
BindingDB Entry DOI: 10.7270/Q2WD41VZ
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419566
PNG
(CHEMBL1934417)
Show SMILES COCCC(C)n1nc(C)c(C(=O)N[C@@H](C)C(C)(C)C)c1NS(=O)(=O)c1ccc(C)cc1 |r|
Show InChI InChI=1S/C23H36N4O4S/c1-15-9-11-19(12-10-15)32(29,30)26-21-20(22(28)24-18(4)23(5,6)7)17(3)25-27(21)16(2)13-14-31-8/h9-12,16,18,26H,13-14H2,1-8H3,(H,24,28)/t16?,18-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 316n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human recombinant FPR1 in expressed in HEK293 cells assessed as inhibition of FMLP-stimulated intracellular calcium mobilisati...


Bioorg Med Chem Lett 22: 532-6 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.090
BindingDB Entry DOI: 10.7270/Q27P90NM
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50418334
PNG
(CHEMBL1770298)
Show SMILES Cc1ccc(s1)C(NC(=O)c1ccccc1O)C(=O)Nc1c(C)cccc1C
Show InChI InChI=1S/C22H22N2O3S/c1-13-7-6-8-14(2)19(13)23-22(27)20(18-12-11-15(3)28-18)24-21(26)16-9-4-5-10-17(16)25/h4-12,20,25H,1-3H3,(H,23,27)(H,24,26)
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 398n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assay


Bioorg Med Chem Lett 21: 6456-60 (2011)


Article DOI: 10.1016/j.bmcl.2011.08.085
BindingDB Entry DOI: 10.7270/Q2WD41VZ
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50418334
PNG
(CHEMBL1770298)
Show SMILES Cc1ccc(s1)C(NC(=O)c1ccccc1O)C(=O)Nc1c(C)cccc1C
Show InChI InChI=1S/C22H22N2O3S/c1-13-7-6-8-14(2)19(13)23-22(27)20(18-12-11-15(3)28-18)24-21(26)16-9-4-5-10-17(16)25/h4-12,20,25H,1-3H3,(H,23,27)(H,24,26)
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 398n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human FPR1 in expressed in HEK293 cells assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation after 5 m...


Bioorg Med Chem Lett 21: 2991-7 (2011)


Article DOI: 10.1016/j.bmcl.2011.03.049
BindingDB Entry DOI: 10.7270/Q2PZ5B2D
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419570
PNG
(CHEMBL1934271)
Show SMILES CCC(CC)n1nc(C)c(C(=O)N[C@@H](C)C(C)(C)C)c1NS(=O)(=O)c1ccc(C)cc1 |r|
Show InChI InChI=1S/C23H36N4O3S/c1-9-18(10-2)27-21(26-31(29,30)19-13-11-15(3)12-14-19)20(16(4)25-27)22(28)24-17(5)23(6,7)8/h11-14,17-18,26H,9-10H2,1-8H3,(H,24,28)/t17-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 398n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human recombinant FPR1 in expressed in HEK293 cells assessed as inhibition of FMLP-stimulated intracellular calcium mobilisati...


Bioorg Med Chem Lett 22: 532-6 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.090
BindingDB Entry DOI: 10.7270/Q27P90NM
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50051690
PNG
(CHEMBL3311137)
Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(cc1)C(=O)c1ccccc1)NC(=O)OC(C)(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O |r|
Show InChI InChI=1/C51H63N5O9/c1-32(2)27-39(53-48(61)42(56-50(64)65-51(5,6)7)30-36-23-25-38(26-24-36)44(57)37-21-15-10-16-22-37)45(58)54-41(29-34-17-11-8-12-18-34)47(60)52-40(28-33(3)4)46(59)55-43(49(62)63)31-35-19-13-9-14-20-35/h8-26,32-33,39-43H,27-31H2,1-7H3,(H,52,60)(H,53,61)(H,54,58)(H,55,59)(H,56,64)(H,62,63)/t39-,40-,41+,42+,43+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 420n/an/an/an/an/an/a



Saga University

Curated by ChEMBL


Assay Description
Antagonist activity at formyl peptide receptor in human HL60 cells assessed as inhibition of fMLP-induced calcium mobilization incubated for 5 mins p...


Bioorg Med Chem 22: 3824-8 (2014)


Article DOI: 10.1016/j.bmc.2014.06.048
BindingDB Entry DOI: 10.7270/Q28S4RK8
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050943
PNG
((S)-2-[(R)-2-((S)-2-{(R)-2-[(S)-2-(3-Isopropyl-ure...)
Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)NC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O
Show InChI InChI=1S/C43H58N6O7/c1-27(2)22-33(46-41(53)36(49-43(56)44-29(5)6)25-31-18-12-8-13-19-31)38(50)47-35(24-30-16-10-7-11-17-30)40(52)45-34(23-28(3)4)39(51)48-37(42(54)55)26-32-20-14-9-15-21-32/h7-21,27-29,33-37H,22-26H2,1-6H3,(H,45,52)(H,46,53)(H,47,50)(H,48,51)(H,54,55)(H2,44,49,56)/t33-,34-,35+,36+,37+/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 500n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM40404
PNG
(UNM000003536701 | [6-ethyl-2-methyl-3-(1-methylben...)
Show SMILES CCc1cc2c(cc1OC(C)=O)oc(C)c(-c1nc3ccccc3n1C)c2=O |(15.91,-2.7,;15.92,-1.16,;14.59,-.39,;13.19,-1.18,;11.82,-.36,;11.82,1.18,;13.19,2.01,;14.59,1.22,;15.92,1.99,;15.91,3.53,;17.24,4.31,;14.58,4.3,;10.48,1.95,;9.15,1.18,;7.82,1.95,;9.15,-.36,;7.82,-1.13,;6.42,-.5,;5.39,-1.64,;3.85,-1.64,;3.08,-2.97,;3.85,-4.31,;5.39,-4.31,;6.16,-2.97,;7.66,-2.65,;8.8,-3.68,;10.48,-1.13,;10.48,-2.67,)|
Show InChI InChI=1S/C22H20N2O4/c1-5-14-10-15-19(11-18(14)28-13(3)25)27-12(2)20(21(15)26)22-23-16-8-6-7-9-17(16)24(22)4/h6-11H,5H2,1-4H3
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
PCBioAssay
n/an/a 500n/an/an/an/an/an/a



NMMLSC

Curated by PubChem BioAssay


Assay Description
University of New Mexico Assay Overview: Assay Support: NIH 1R03MH076381-01 Assay for Formylpeptide Receptor Family Ligands PI: Bruce S. Edwards, Ph...


PubChem Bioassay (2007)


BindingDB Entry DOI: 10.7270/Q2TB1590
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50050942
PNG
((S)-2-[(R)-4-Methyl-2-((S)-2-{(R)-4-methyl-2-[(S)-...)
Show SMILES CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)Nc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O
Show InChI InChI=1S/C46H56N6O7/c1-30(2)25-36(49-44(56)39(28-33-19-11-6-12-20-33)52-46(59)47-35-23-15-8-16-24-35)41(53)50-38(27-32-17-9-5-10-18-32)43(55)48-37(26-31(3)4)42(54)51-40(45(57)58)29-34-21-13-7-14-22-34/h5-24,30-31,36-40H,25-29H2,1-4H3,(H,48,55)(H,49,56)(H,50,53)(H,51,54)(H,57,58)(H2,47,52,59)/t36-,37-,38+,39+,40+/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 500n/an/an/an/an/an/a



Johnson Matthey Biomedical Research

Curated by ChEMBL


Assay Description
Antagonistic activity was determined by measuring the ability to inhibit superoxide production(stimulated by fMLF) using human neutrophils


J Med Chem 39: 1013-5 (1996)


Article DOI: 10.1021/jm950908d
BindingDB Entry DOI: 10.7270/Q2TD9WF6
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50418335
PNG
(CHEMBL1770297)
Show SMILES CCOc1ccc2oc(C(=O)NC(CCSC)c3nc4ccccc4[nH]3)c(C)c2c1
Show InChI InChI=1S/C23H25N3O3S/c1-4-28-15-9-10-20-16(13-15)14(2)21(29-20)23(27)26-19(11-12-30-3)22-24-17-7-5-6-8-18(17)25-22/h5-10,13,19H,4,11-12H2,1-3H3,(H,24,25)(H,26,27)
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 501n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assay


Bioorg Med Chem Lett 21: 6456-60 (2011)


Article DOI: 10.1016/j.bmcl.2011.08.085
BindingDB Entry DOI: 10.7270/Q2WD41VZ
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419380
PNG
(CHEMBL1916283)
Show SMILES C[C@@H](NC(=O)c1c(C)nn(c1NS(=O)(=O)c1ccc(C)cc1)-c1ccccc1)C(C)(C)C |r|
Show InChI InChI=1S/C24H30N4O3S/c1-16-12-14-20(15-13-16)32(30,31)27-22-21(23(29)25-18(3)24(4,5)6)17(2)26-28(22)19-10-8-7-9-11-19/h7-15,18,27H,1-6H3,(H,25,29)/t18-/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 501n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assay


Bioorg Med Chem Lett 21: 6456-60 (2011)


Article DOI: 10.1016/j.bmcl.2011.08.085
BindingDB Entry DOI: 10.7270/Q2WD41VZ
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50419373
PNG
(CHEMBL1916272)
Show SMILES CCC(CC)NC(=O)c1c(C)nn(c1NS(=O)(=O)c1ccc(C)cc1)-c1ccccc1
Show InChI InChI=1S/C23H28N4O3S/c1-5-18(6-2)24-23(28)21-17(4)25-27(19-10-8-7-9-11-19)22(21)26-31(29,30)20-14-12-16(3)13-15-20/h7-15,18,26H,5-6H2,1-4H3,(H,24,28)
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/a 501n/an/an/an/an/an/a



AstraZeneca

Curated by ChEMBL


Assay Description
Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assay


Bioorg Med Chem Lett 21: 6456-60 (2011)


Article DOI: 10.1016/j.bmcl.2011.08.085
BindingDB Entry DOI: 10.7270/Q2WD41VZ
More data for this
Ligand-Target Pair
fMet-Leu-Phe receptor 1/2


(Homo sapiens (Human))
BDBM50026915
PNG
(CHEMBL2372486)
Show SMILES [H][C@]1(NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@](O)(NC(=O)[C@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CN(C)C1=O)C(C)C)[C@@H](C)O |r|
Show InChI InChI=1/C63H113N11O14/c1-24-25-26-40(16)52(77)51-57(82)68-49(42(18)75)60(85)70(19)32-48(76)65-43(27-33(2)3)54(79)66-44(28-34(4)5)58(83)71(20)46(30-36(8)9)55(80)64-41(17)53(78)69-63(88,39(14)15)62(87)72(21)47(31-37(10)11)56(81)67-45(29-35(6)7)59(84)73(22)50(38(12)13)61(86)74(51)23/h24-25,33-47,49-52,75,77,88H,26-32H2,1-23H3,(H,64,80)(H,65,76)(H,66,79)(H,67,81)(H,68,82)(H,69,78)/b25-24+/t40-,41+,42-,43+,44+,45+,46-,47+,49+,50+,51+,52-,63+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
PubMed
n/an/a 560n/an/an/an/an/an/a



Strasbourg 1 University

Curated by ChEMBL


Assay Description
Inhibitory activity against human formylpeptide receptor (FPR) of human leukemia HL-60 cells


J Med Chem 45: 4613-28 (2002)


BindingDB Entry DOI: 10.7270/Q2571CQX
More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 469 total )  |  Next  |  Last  >>
Jump to: